» Articles » PMID: 34512154

Preclinical and Clinical Progress for HDAC As a Putative Target for Epigenetic Remodeling and Functionality of Immune Cells

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2021 Sep 13
PMID 34512154
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Genetic changes are difficult to reverse; thus, epigenetic aberrations, including changes in DNA methylation, histone modifications, and noncoding RNAs, with potential reversibility, have attracted attention as pharmaceutical targets. The current paradigm is that histone deacetylases (HDACs) regulate gene expression via deacetylation of histone and nonhistone proteins or by forming corepressor complexes with transcription factors. The emergence of epigenetic tools related to HDACs can be used as diagnostic and therapeutic markers. HDAC inhibitors that block specific or a series of HDACs have proven to be a powerful therapeutic treatment for immune-related diseases. Here, we summarize the various roles of HDACs and HDAC inhibitors in the development and function of innate and adaptive immune cells and their implications for various diseases and therapies.

Citing Articles

Insights into the regulatory role of epigenetics in moyamoya disease: Current advances and future prospectives.

Xu S, Chen T, Yu J, Wan L, Zhang J, Chen J Mol Ther Nucleic Acids. 2024; 35(3):102281.

PMID: 39188306 PMC: 11345382. DOI: 10.1016/j.omtn.2024.102281.


Emerging roles and therapeutic implications of HDAC2 and IL-17A in steroid-resistant asthma.

Ouyang L, Su G, Quan J, Xiong Z, Lai T Chin Med J Pulm Crit Care Med. 2024; 1(2):108-112.

PMID: 39170824 PMC: 11332885. DOI: 10.1016/j.pccm.2023.04.003.


Neutrophil Elastase Degrades Histone Deacetylases and Sirtuin 1 in Primary Human Monocyte Derived Macrophages.

Zheng S, Bulut G, Kummarapurugu A, Ma J, Voynow J Int J Mol Sci. 2024; 25(8).

PMID: 38673851 PMC: 11050352. DOI: 10.3390/ijms25084265.


Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review.

Zhang Y, Zhang G, Wang Y, Ye L, Peng L, Shi R Front Oncol. 2024; 14:1324859.

PMID: 38450195 PMC: 10915758. DOI: 10.3389/fonc.2024.1324859.


Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer.

Lin Y, Jing X, Chen Z, Pan X, Xu D, Yu X Theranostics. 2023; 13(13):4574-4600.

PMID: 37649598 PMC: 10465215. DOI: 10.7150/thno.86928.


References
1.
Kim Y, Han S, Lee J . Histone deacetylase inhibitors suppress CXCR4-mediated dendritic cell migration by regulation of maturation process. Cell Immunol. 2013; 284(1-2):139-45. DOI: 10.1016/j.cellimm.2013.07.014. View

2.
Guo J, Wang Y, Jiang P, Yao H, Zhao C, Hu X . Sodium butyrate alleviates lipopolysaccharide-induced endometritis in mice through inhibiting inflammatory response. Microb Pathog. 2019; 137:103792. DOI: 10.1016/j.micpath.2019.103792. View

3.
Lee H, Lee E, Do G, Moon E, Quan F, Kim I . Histone deacetylase inhibitor MGCD0103 protects the pancreas from streptozotocin-induced oxidative stress and β-cell death. Biomed Pharmacother. 2018; 109:921-929. DOI: 10.1016/j.biopha.2018.10.163. View

4.
Singh V, Bhatia H, Kumar A, De Oliveira A, Fiebich B . Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia. Neuroscience. 2014; 265:147-57. DOI: 10.1016/j.neuroscience.2014.01.037. View

5.
Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View